Decitabine
| Code | Size | Price |
|---|
| CDX-A0563-M005 | 5 mg | £48.00 |
Quantity:
| CDX-A0563-M010 | 10 mg | £78.00 |
Quantity:
| CDX-A0563-M050 | 50 mg | £280.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
+20°C
Documents
Further Information
Alternate Names/Synonyms:
5-Aza-2'-deoxycytidine; DAC; 2'-Deoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; NSC 127716
Appearance:
White to off-white powder.
CAS:
2353-33-5
EClass:
32160000
Form (Short):
liquid
GHS Symbol:
GHS07,GHS08
Handling Advice:
Protect from light and moisture.
Hazards:
H302,H315,H319,H335,H341,H360
InChi:
InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1
InChiKey:
XAUDJQYHKZQPEU-KVQBGUIXSA-N
Long Description:
Chemical. CAS: 2353-33-5. Formula: C8H12N4O4. MW: 228.21. Decitabine is an epigenetic modifier that inhibits DNA methyltransferase activity which results in DNA demethylation (hypomethylation) and gene activation by remodeling "opening" chromatin. This cytosine analog incorporates into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects. Decitabine is a potent antileukaemic agent with activity in the treatment of haematological malignancies such as acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and myelodysplastic syndrome (preleukaemia) and has been suggested to reverse chemotherapy resistance in several cancer types. It is used as a chemotherapeutic agent, suppresses growth of human tumor cell lines, shown to reverse embryonic stem cell differentiation and prevent atherosclerosis lesion formation and reduces the production of inflammatory cytokines by macrophages.
MDL:
MFCD00043011
Molecular Formula:
C8H12N4O4
Molecular Weight:
228.21
Package Type:
Vial
Precautions:
P201,P261,P281,P305+P351+P338,P308+P313
Product Description:
Decitabine is an epigenetic modifier that inhibits DNA methyltransferase activity which results in DNA demethylation (hypomethylation) and gene activation by remodeling "opening" chromatin. This cytosine analog incorporates into DNA, inhibit DNA methyltransferases, and cause hypomethylation of cytosine residues in the absence of any significant mutagenic effects. Decitabine is a potent antileukaemic agent with activity in the treatment of haematological malignancies such as acute myeloid leukaemia (AML), chronic myeloid leukaemia (CML) and myelodysplastic syndrome (preleukaemia) and has been suggested to reverse chemotherapy resistance in several cancer types. It is used as a chemotherapeutic agent, suppresses growth of human tumor cell lines, shown to reverse embryonic stem cell differentiation and prevent atherosclerosis lesion formation and reduces the production of inflammatory cytokines by macrophages.
Purity:
>99% (HPLC)
Signal word:
Danger
SMILES:
O[C@H]1C[C@H](N2C(N=C(N)N=C2)=O)O[C@@H]1CO
Solubility Chemicals:
Soluble in DMSO (30mg/ml), DMF (20mg/ml) or water (1mg/ml).
Source / Host:
Synthetic
Transportation:
Non-hazardous
UNSPSC Category:
Biochemical Reagents
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at RT.
References
(1) T. Ando, et al.; Leukemia 14, 1915 (2000) | (2) D. Lavelle, et al.; Leuk. Res. 27, 999 (2003) | (3) No Author; Drugs R.D. 4, 179 (2003) (Review) | (4) J. Lyons, et al.; Curr. Opin. Investig. Drugs 4, 1442 (2003) (Review) | (5) C. Stresemann & F. Lyko; Int. J. Cancer 123, 8 (2008) (Review) | (6) M. Al-Salihi, et al.; Epigenetics 6, 1021 (2011) | (7) V.V. Konkankit, et al.; J. Transl. Med. 9, 192 (2011) | (8) D. Yang, et al.; J. Immunol. 188, 4441 (2012) | (9) D.Y. Shin, et al.; Int. J. Oncol. 41, 910 (2012) | (10) M. Soncini, et al.; Biochim. Biophys. Acta 1832, 114 (2013) | (11) J. Nie, et al.; Cancer Lett. 354, 12 (2014) (Review) | (12) X. Li, et al.; Expert Rev. Clin. Immunol. 11, 363 (2015) (Review) | (13) S. Ramakrishnan, et al.; Cell Death Dis. 8, 3217 (2017) | (14) R.S. Seelan, et al.; Drug Metab. Rev. 50, 193 (2018) (Review)